미세잔존질환 검사 시장 : 검사 유형, 검체 유형, 용도 분야, 최종 사용자 업계별 - 세계 예측(2026-2032년)

The Minimal Residual Disease Testing Market was valued at USD 2.08 billion in 2025 and is projected to grow to USD 2.31 billion in 2026, with a CAGR of 11.55%, reaching USD 4.47 billion by 2032.

Minimal residual disease (MRD) testing has evolved from a specialized research assay into a pivotal clinical tool that informs prognosis, guides therapeutic intensity, and enables adaptive treatment strategies across hematologic and selected solid tumor indications. Clinicians and laboratory leaders now view MRD not merely as a biomarker but as a decision-making instrument that affects remission assessment, relapse surveillance, and eligibility for novel therapies. Consequently, the diagnostic landscape is responding with a broader array of analytical approaches, enhanced sensitivity thresholds, and workflows designed to integrate results into fast-moving clinical pathways.

The introduction of more sensitive platforms and the alignment of clinical trial endpoints with MRD status have accelerated clinical adoption, while parallel advances in sample handling, quality control, and reporting standards are beginning to reduce variability across testing sites. As a result, MRD testing occupies an intersection of clinical urgency and technological innovation: it must deliver reproducible, clinically actionable results within timelines that influence therapeutic choices. Understanding the interplay between analytical capability, clinical validation, and operational readiness is therefore essential for stakeholders seeking to scale MRD testing from specialized centers to routine care settings.

Transformative shifts redefining minimal residual disease testing driven by analytical innovation clinical validation and integration into therapeutic decision frameworks

The MRD landscape is undergoing transformative shifts driven by convergence between high-sensitivity molecular techniques, refined cellular assays, and digital analytics. Innovations such as targeted next-generation sequencing panels tailored for low-allele-frequency detection, digital PCR approaches that deliver absolute quantitation, and multi-parameter flow cytometry optimized for standardized immunophenotyping are collectively raising the floor of detectability. Concurrently, improvements in sample preservation, centralized reference testing, and cross-platform validation studies are reducing inter-laboratory variance and increasing clinician confidence in MRD readouts.

Beyond raw analytical progress, the integration of MRD into clinical trial design and regulatory pathways is reshaping commercial and clinical incentives. As MRD is increasingly used as an early surrogate endpoint for therapeutic efficacy, sponsors are structuring trials and regulatory engagements to demonstrate how MRD-informed dosing or duration strategies improve patient outcomes. Additionally, digital infrastructure-ranging from laboratory information systems to cloud-based variant interpretation-supports faster result delivery and federated analytics, which in turn enable scalable clinical decision support. Together, these shifts are accelerating MRD from a niche diagnostic towards a standardized element of precision oncology workflows.

Assessing the cumulative effects of United States tariff policy adjustments in 2025 on supply chains cost structures and clinical access to minimal residual disease diagnostics

Tariff changes enacted in 2025 have introduced a new layer of operational complexity for stakeholders that depend on a globally integrated supply chain for instruments, reagents, and consumables. Increased duties on imported specialized equipment and assay components raise unit costs and create incentive pressures to adjust procurement strategies. For clinical laboratories and diagnostic manufacturers, these cost pressures can translate into tighter margins, delayed capital renewal cycles for high-cost instrumentation, and a need to reassess pricing or service models to maintain viability without compromising clinical access.

In addition to direct cost effects, tariffs contribute to supply chain friction that can lengthen lead times for critical reagents and spare parts. Extended replenishment cycles exacerbate inventory risk for high-throughput centers and may compel laboratories to diversify supplier portfolios or to qualify alternative assay formats that rely on locally sourced inputs. Policy responses and commercial mitigations have begun to emerge: some organizations are accelerating regional manufacturing investments, while others are negotiating long-term supply agreements that allocate tariff risk. Clinically, the net effect is uneven; well-resourced systems can absorb short-term disruption through internal buffering and strategic procurement, whereas resource-constrained hospitals and diagnostic networks may face delays or restricted access to advanced MRD platforms. Consequently, stakeholders must factor in tariff-induced cost and availability shifts when projecting technology adoption timelines and when designing resilient operational models.

Key segmentation insights demonstrating how test modalities clinical applications and end-user verticals combine to determine adoption priorities and value creation

A segmentation-aware perspective reveals how analytical modality, clinical indication, and end-user type interact to shape adoption pathways and value creation for MRD testing. Test types such as cytogenetics with chromosomal microarray and FISH retain critical roles for structural aberration detection in certain hematologic contexts, but they coexist with flow cytometry approaches where multi-parameter and single-parameter platforms offer complementary cellular resolution. Molecular modalities occupy a central position: targeted next-generation sequencing panels and whole-genome sequencing provide sensitivity and breadth for mutation-based MRD assessment, while digital PCR and quantitative PCR deliver rapid, cost-efficient quantitation for predefined targets.

Application areas further guide which technical profile is prioritized. In leukemia subtypes including acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia, both molecular and immunophenotypic assays are used to provide orthogonal confirmation of remission status. Lymphoma testing, encompassing Hodgkin's and non-Hodgkin's variants, requires tailored assay designs that balance sensitivity against tumor heterogeneity. Multiple myeloma and selected solid tumors such as breast and colorectal cancer demand bespoke MRD strategies that reflect disease biology and available therapeutic options. Finally, end-user verticals-academic and research institutes, biopharmaceutical companies, diagnostic laboratories, and hospitals-each press unique requirements. Academic centers prioritize methodological innovation and translational research, biopharmaceutical sponsors emphasize standardized assays for clinical trials, diagnostic laboratories focus on throughput and cost-efficiency, and hospitals prioritize turnaround time and integration with electronic medical records. Understanding these interdependencies enables more precise alignment of product design, clinical evidence generation, and commercial models.

Regional strategic intelligence mapping adoption trends infrastructure strengths reimbursement dynamics and collaborative ecosystems across the Americas Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on MRD deployment because regulatory regimes, reimbursement frameworks, and laboratory infrastructure diverge significantly across geographies. In the Americas, established reference laboratories and a high density of clinical trials support relatively rapid uptake of novel MRD platforms, although payer coverage variability can constrain routine use outside of trial settings. The region's diagnostic networks also serve as hubs for innovation, attracting partnerships between clinical centers and industry that accelerate evidence generation and adoption.

Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European markets benefit from consolidated reimbursement pathways and robust laboratory accreditation systems, while many countries in the Middle East and Africa face capacity constraints that limit access to advanced MRD testing. Collaborative procurement mechanisms and regional reference laboratories are emerging as pragmatic solutions to bridge gaps. In the Asia-Pacific, investment in domestic manufacturing, rising clinical trial activity, and expanding hospital networks are driving uptake, though regulatory timelines and local validation requirements necessitate careful market entry planning. Collectively, these regional patterns imply that commercialization strategies must be tailored: scalable centralized testing models may work in some geographies, whereas decentralized point-of-care or near-patient approaches could better address access and timeliness in others.

Key company-level insights highlighting partnerships vertical integration evidence generation and service differentiation strategies that shape competitive positioning

Contemporary competitive dynamics in the MRD space are characterized by a blend of specialization and integration. Diagnostic developers and platform providers differentiate through analytical sensitivity, assay robustness, and ease of clinical workflow integration, while reagent suppliers compete on consistency, lot-to-lot reliability, and regulatory-compliant supply chains. Platform integrators and clinical laboratory networks are increasingly offering bundled services that combine instrumentation, software-enabled interpretation, and reporting templates that align with clinician decision needs.

Partnership models stand out as an accelerant: collaborations between diagnostic firms and biopharmaceutical sponsors enable co-development of companion MRD assays for therapeutic programs, while alliances with academic centers provide validation cohorts and real-world evidence. In parallel, some organizations are pursuing vertical integration-bringing assay development, manufacturing, and clinical service delivery under one operational umbrella-to reduce supply risk and capture greater downstream value. Service differentiation extends beyond analytical performance to include training, accreditation support, and post-market surveillance capabilities; the ability to demonstrate clinical utility through peer-reviewed evidence increasingly separates market leaders from niche players. These competitive behaviors suggest a maturing market where strategic alignment with clinical stakeholders and operational excellence determine long-term success.

Actionable and prioritized recommendations for industry leaders to accelerate adoption mitigate risk and align clinical evidence operational execution and payer engagement

Industry leaders seeking to accelerate MRD adoption should pursue a pragmatic set of actions that align clinical utility with operational feasibility. First, prioritize robust clinical evidence generation by embedding MRD endpoints into prospective therapeutic trials and by conducting real-world outcome studies that demonstrate how MRD-guided decisions alter patient trajectories. Second, strengthen supply chain resilience by qualifying alternative suppliers, building regional inventory buffers, and exploring localized production for high-risk components to mitigate tariff and logistics exposures.

Third, engage payers early to translate clinical benefit into reimbursement pathways, using cost-effectiveness models and phased coverage strategies tied to clinical indications. Fourth, invest in interoperable digital infrastructure that links laboratory results with electronic medical records and decision-support tools, thereby reducing clinician friction and ensuring timely therapeutic adjustments. Fifth, adopt flexible commercial models such as performance-based pricing or tiered service offerings to lower barriers for adoption in resource-constrained settings. Lastly, commit to workforce development through standardized training and accreditation programs that ensure consistent assay performance across decentralized testing environments. Collectively, these actions balance immediate operational needs with longer-term strategic positioning in a rapidly evolving diagnostic landscape.

Transparent research methodology explaining data sources expert engagements analytical frameworks and validation approaches used to derive insights on minimal residual disease testing

This analysis synthesizes evidence from a multi-pronged research approach designed to triangulate findings and reduce bias. The methodology combined systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and technical white papers with targeted primary research comprising interviews with clinical experts, laboratory directors, biopharma development leads, and supply chain specialists. Where available, assay performance data was compared across published validation studies and regulatory summaries to assess concordance and reproducibility.

Analytical frameworks included technology readiness assessment, value-chain mapping, and stakeholder impact analysis to understand where bottlenecks and opportunities converge. Regional policy and tariff impacts were modeled qualitatively through scenario analysis that considered procurement pathways, lead-time sensitivity, and the feasibility of regional manufacturing. Findings were iteratively validated through expert review sessions to reconcile divergent perspectives and to highlight limitations. Key methodological limitations include variability in published assay documentation, evolving regulatory guidance, and the inherent uncertainty around future policy adjustments; these factors were explicitly considered when framing conclusions and recommendations.

Concluding synthesis emphasizing the opportunities operational challenges and strategic priorities that will determine the future trajectory of minimal residual disease diagnostics

In summary, MRD testing stands at a pivotal juncture where analytical advances, clinical validation efforts, and commercial strategies converge to enable broader clinical utility. The diagnostic modalities available today collectively offer a toolkit that can be matched to disease biology and care delivery constraints, but successful scale-up depends on rigorous evidence generation, resilient supply chains, and payer engagement. Policy shifts such as tariffs and evolving reimbursement landscapes add complexity, requiring adaptive commercialization and operational planning.

For stakeholders across the ecosystem, the path forward centers on collaboration: clinical sites and laboratories must align on standardized practices, industry must invest in reproducible assay design and evidence, and payers and regulators should work with sponsors to define pathways that translate MRD detection into meaningful clinical decisions. Executing on these priorities will determine whether MRD fulfills its promise as a routine instrument of precision oncology or remains confined to specialized use cases. The balance of technical capability and system-level readiness will ultimately shape patient access and therapeutic innovation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimal Residual Disease Testing Market, by Test Type

• 8.1. Cytogenetics
  • 8.1.1. Chromosomal microarray
  • 8.1.2. Fluorescence in situ hybridization (FISH)
• 8.2. Flow Cytometry
  • 8.2.1. Multi-parameter flow cytometry
  • 8.2.2. Single-parameter flow cytometry
• 8.3. Next-Generation Sequencing (NGS)
  • 8.3.1. Targeted sequencing
  • 8.3.2. Whole genome sequencing
• 8.4. Polymerase Chain Reaction (PCR)
  • 8.4.1. Digital PCR
  • 8.4.2. Quantitative PCR

9. Minimal Residual Disease Testing Market, by Sample Type

• 9.1. Blood
  • 9.1.1. Plasma
  • 9.1.2. Serum
• 9.2. Bone Marrow
• 9.3. Cerebrospinal Fluid (CSF)
• 9.4. Tissue Biopsy
• 9.5. Urine

10. Minimal Residual Disease Testing Market, by Application Areas

• 10.1. Leukemia
  • 10.1.1. Acute Lymphoblastic Leukemia (ALL)
  • 10.1.2. Acute Myeloid Leukemia (AML)
  • 10.1.3. Chronic Lymphocytic Leukemia (CLL)
• 10.2. Lymphoma
  • 10.2.1. Hodgkin's lymphoma
  • 10.2.2. Non-Hodgkin's lymphoma
• 10.3. Multiple Myeloma
• 10.4. Solid Tumors
  • 10.4.1. Breast cancer
  • 10.4.2. Colorectal cancer

11. Minimal Residual Disease Testing Market, by End-User Vertical

• 11.1. Academic & Research Institutes
• 11.2. Biopharmaceutical Companies
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals

12. Minimal Residual Disease Testing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Minimal Residual Disease Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Minimal Residual Disease Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Minimal Residual Disease Testing Market

16. China Minimal Residual Disease Testing Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Adaptive Biotechnologies Corporation
• 17.6. Agilus Diagnostics Ltd.
• 17.7. Amgen Inc.
• 17.8. ARUP Laboratories
• 17.9. AstraZeneca PLC
• 17.10. Asuragen Inc. by Bio-Techne Corporation
• 17.11. Bio-Rad Laboratories, Inc.
• 17.12. Bristol-Myers Squibb Company
• 17.13. C2I Genomics Inc.
• 17.14. Cergentis B.V.
• 17.15. Exact Sciences Corporation
• 17.16. F. Hoffmann-La Roche Ltd.
• 17.17. Genetron Holdings Limited
• 17.18. GRAIL, LLC by Illumina, Inc.
• 17.19. Guardant Health, Inc.
• 17.20. Integrated DNA Technologies, Inc.
• 17.21. Invivoscribe, Inc.
• 17.22. Kite Pharma, Inc. by Gilead Sciences, Inc.
• 17.23. Laboratory Corporation of America Holdings
• 17.24. Mdxhealth BV
• 17.25. MedGenome Inc
• 17.26. Mission Bio, Inc.
• 17.27. Myriad Genetics, Inc.
• 17.28. Natera Inc.
• 17.29. NeoGenomics Laboratories, Inc.
• 17.30. OPKO Health, Inc.
• 17.31. Quest Diagnostics incorporated
• 17.32. Sysmex Corporation
• 17.33. Veracyte, Inc.